Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in share interests arising from dividend reinvestment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On January 4, 2013, the following individuals purchased Ordinary Shares through the reinvestment of dividends within an Individual Savings Account (ISA) at a price of 1,368 pence per share:
- Sir Andrew Witty: 44 shares
- Mr S M Bicknell: 96 shares
- Mr D S Redfern: 19 shares
- Mrs V A Whyte: 16 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Share purchase price was 1,368 pence per Ordinary Share.
- Transactions were executed on January 4, 2013, via dividend reinvestment.
- The total number of shares acquired by the named directors and officers was 175.
- The Company was advised of these transactions on January 7, 2013.